Dogwood Therapeutics Inc (DWTX)

$4.90 +0.02 (0.41%)
Market Cap 9.35M
Revenue (ttm) 0.00
Net Income (ttm) -12.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 14,024
Avg Vol 17,738
Day's Range N/A - N/A
Shares Out 1.91M
Stochastic %K 44%
Beta 1.79
Analysts Strong Sell
Price Target $17.00

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 620 8655
Website: dwtx.com
Address:
44 Milton Avenue, Alpharetta, United States
Lalalilala
Lalalilala Sep. 10 at 6:25 PM
$DWTX 40% more shares than the last pump.....if Q4 results are positive, I think $14/15 would be a good price. But not beyond that at this stage. If it fails, return $1.50 and it's over. Place your bets.
1 · Reply
Skitt2k
Skitt2k Sep. 8 at 12:47 AM
$DWTX when it hit $29 was that because of positive clinical results?
0 · Reply
Skitt2k
Skitt2k Sep. 5 at 7:41 AM
$DWTX when this does eventually pop off, are we expecting a break through the 30's?
2 · Reply
cheesedonkey
cheesedonkey Sep. 4 at 3:58 PM
$DWTX
1 · Reply
Drainomight
Drainomight Sep. 3 at 4:57 PM
$DWTX No one is selling because they know what’s up
1 · Reply
CurrencyArbGroup
CurrencyArbGroup Aug. 23 at 11:27 AM
$DWTX DWTX Inc is a ticker that may be incorrect or represent a delisted company
3 · Reply
Drainomight
Drainomight Aug. 22 at 2:23 PM
$DWTX
1 · Reply
Skitt2k
Skitt2k Aug. 22 at 6:26 AM
$DWTX God is this thing due..
0 · Reply
Xvool
Xvool Aug. 21 at 12:33 PM
$DWTX pending data release - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) 🚨Phase 2b study interim data readout remains on track as projected for Q4 2025 -
0 · Reply
ZacksSCR
ZacksSCR Aug. 20 at 8:20 PM
$DWTX: Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron® Trial; Interim Read Out in 4Q25 Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron® Trial; Interim Read Out in 4Q25 https://buff.ly/jHpJkDG
1 · Reply
Latest News on DWTX
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 14 days ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 9:00 AM EDT - 5 weeks ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 7, 2025, 1:08 PM EDT - 5 weeks ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Aug 6, 2025, 9:15 AM EDT - 6 weeks ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Jun 3, 2025, 9:15 AM EDT - 3 months ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 8, 2025, 9:00 AM EDT - 4 months ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

May 1, 2025, 8:30 AM EDT - 4 months ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 11, 2025, 9:15 AM EDT - 5 months ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Apr 3, 2025, 9:00 AM EDT - 5 months ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 31, 2025, 3:45 PM EDT - 6 months ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 18, 2025, 8:45 AM EDT - 6 months ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Mar 13, 2025, 9:00 AM EDT - 6 months ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 9:41 AM EDT - 1 year ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Jul 23, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 22, 2024, 1:30 PM EDT - 1 year ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 1 year ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 1 year ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

May 11, 2024, 11:44 PM EDT - 1 year ago

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:45 AM EDT - 1 year ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

May 2, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Mar 26, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Feb 28, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 22, 2024, 9:00 AM EST - 1 year ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Jan 2, 2024, 7:05 AM EST - 1 year ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 11:21 AM EST - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Oct 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 18, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Sep 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 10:05 AM EDT - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Aug 9, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Jul 17, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 25, 2023, 4:05 PM EDT - 2 years ago

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 15, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

Virios Therapeutics Announces First Quarter 2023 Financial Results

May 11, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces First Quarter 2023 Financial Results

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

May 4, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Apr 24, 2023, 4:15 PM EDT - 2 years ago

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

Mar 7, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Feb 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

Jan 5, 2023, 7:00 AM EST - 2 years ago

Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Nov 29, 2022, 7:05 AM EST - 3 years ago

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2022 Results - Earnings Call Transcript

Nov 14, 2022, 2:37 PM EST - 3 years ago

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2022 Results - Earnings Call Transcript

Lalalilala
Lalalilala Sep. 10 at 6:25 PM
$DWTX 40% more shares than the last pump.....if Q4 results are positive, I think $14/15 would be a good price. But not beyond that at this stage. If it fails, return $1.50 and it's over. Place your bets.
1 · Reply
Skitt2k
Skitt2k Sep. 8 at 12:47 AM
$DWTX when it hit $29 was that because of positive clinical results?
0 · Reply
Skitt2k
Skitt2k Sep. 5 at 7:41 AM
$DWTX when this does eventually pop off, are we expecting a break through the 30's?
2 · Reply
cheesedonkey
cheesedonkey Sep. 4 at 3:58 PM
$DWTX
1 · Reply
Drainomight
Drainomight Sep. 3 at 4:57 PM
$DWTX No one is selling because they know what’s up
1 · Reply
CurrencyArbGroup
CurrencyArbGroup Aug. 23 at 11:27 AM
$DWTX DWTX Inc is a ticker that may be incorrect or represent a delisted company
3 · Reply
Drainomight
Drainomight Aug. 22 at 2:23 PM
$DWTX
1 · Reply
Skitt2k
Skitt2k Aug. 22 at 6:26 AM
$DWTX God is this thing due..
0 · Reply
Xvool
Xvool Aug. 21 at 12:33 PM
$DWTX pending data release - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) 🚨Phase 2b study interim data readout remains on track as projected for Q4 2025 -
0 · Reply
ZacksSCR
ZacksSCR Aug. 20 at 8:20 PM
$DWTX: Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron® Trial; Interim Read Out in 4Q25 Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron® Trial; Interim Read Out in 4Q25 https://buff.ly/jHpJkDG
1 · Reply
Xvool
Xvool Aug. 20 at 7:40 PM
$DWTX $4.86 🚨 Pending Phase 2 study results 🚨 *ONLY ->1 million outstanding shares 1 million float ! $7 cash per share on balance sheet (per finviz data below) Very thin on L2 has ran from $2 to $28 in 1 day .. !
0 · Reply
HeyHoser
HeyHoser Aug. 20 at 2:48 PM
$DWTX AGAIN I ADD $4.7
1 · Reply
ByBi
ByBi Aug. 18 at 7:12 PM
$DWTX It seems like they updated their corpo presentation and took off the incoming financing for imc1 and imc2. What is there to think about ?? No more partnership ?? So if ck buy back their halneuron asset accroding to the agreement, what's next ? This is their presentations over time, with their latest updated one. 👀👇
3 · Reply
cheesedonkey
cheesedonkey Aug. 18 at 2:39 PM
$DWTX
0 · Reply
Xvool
Xvool Aug. 18 at 2:35 PM
$DWTX $5.10 -> 1 Million outstanding with phase 2 data pending release 🚨 *$7 cash per share on balance sheet*
1 · Reply
2TM
2TM Aug. 15 at 5:43 PM
$TIVC The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Low float no shares to borrow. $GME $DWTX $CHWY. $U.
0 · Reply
gmc9
gmc9 Aug. 15 at 9:45 AM
$OTLK this can easily follow the steps of $DWTX from $2 to $27 on a news day 🔥
0 · Reply
Skitt2k
Skitt2k Aug. 11 at 5:42 AM
$DWTX they are reporting earnings this Wednesday. Wonder if it will bring any action..
1 · Reply
Drainomight
Drainomight Aug. 9 at 11:27 PM
$DWTX sleeping giant
2 · Reply
Cbtank663
Cbtank663 Aug. 7 at 5:18 PM
$DWTX https://finviz.com//news/132347/dogwood-therapeutics-announces-enrollment-of-first-fifty-patients-in-ongoing-halneuron-phase-2b-trial
0 · Reply
somaopp
somaopp Aug. 5 at 12:45 PM
$DWTX significant PM vol? perhaps news of vertex sodium channel blocker trial failure??
0 · Reply
biostocktrader_number_1
biostocktrader_number_1 Aug. 4 at 8:13 PM
$DWTX when will this fly?
0 · Reply